Topoisomerase inhibitor

Last updated

Topoisomerase inhibitors are chemical compounds that block the action of topoisomerases, which are broken into two broad subtypes: type I topoisomerases (TopI) and type II topoisomerases (TopII). [1] [2] [3] Topoisomerase plays important roles in cellular reproduction and DNA organization, as they mediate the cleavage of single and double stranded DNA to relax supercoils, untangle catenanes, and condense chromosomes in eukaryotic cells. [1] [2] [3] Topoisomerase inhibitors influence these essential cellular processes. Some topoisomerase inhibitors prevent topoisomerases from performing DNA strand breaks while others, deemed topoisomerase poisons, associate with topoisomerase-DNA complexes and prevent the re-ligation step of the topoisomerase mechanism. [3] These topoisomerase-DNA-inhibitor complexes are cytotoxic agents, as the un-repaired single and double stranded DNA breaks that they cause can lead to apoptosis and cell death. [2] [3] Because of this ability to induce apoptosis, topoisomerase inhibitors have gained interest as therapeutics against infectious and cancerous cells.

Contents

History

In the 1940s, great strides were made in the field of antibiotic discovery by researchers like Albert Schatz, Selman A. Waksman, and H. Boyd Woodruff that inspired significant effort to be allocated to the search for novel antibiotics. [4] [5] [6] [7] Studies searching for antibiotic and anticancer agents in the mid to late 20th century have illuminated the existence of numerous unique families of both TopI and TopII inhibitors, with the 1960s alone resulting in the discovery of the camptothecin, anthracycline and epipodophyllotoxin classes. [8] Knowledge of the first topoisomerase inhibitors, and their medical potential as anticancer drugs and antibiotics, predates the discovery of the first topoisomerase (Escherichia. coli omega protein, a TopI) by Jim Wang in 1971. [9] [10] [11] In 1976, Gellert et al. detailed the discovery of the bacterial TopII DNA gyrase and discussed its inhibition when introduced to coumarin and quinolone class inhibitors, sparking greater interest in topoisomerase-targeting antibiotic and antitumor agents. [3] [12] Topoisomerase inhibitors have been used as important experimental tools that have contributed to the discovery of some topoisomerases, as the quinolone nalidixic acid helped elucidate the bacterial TopII proteins it binds to. [11] Topoisomerase inhibitor classes have been derived from a wide variety of disparate sources, with some being natural products first extracted from plants (camptothecin, [10] etoposide [13] ) or bacterial samples (doxorubicin, [14] indolocarbazole [15] ), while others possess purely synthetic, and often accidental, origins (quinolone, [11] indenoisoquinoline [16] ). After their initial discoveries, the structures of these classes have been fine tuned through the creation of derivatives in order to make safer, more effective, and are more easily administered variants. [10] [11] [16] [17] Currently, topoisomerase inhibitors hold a prominent place among antibiotics and anticancer drugs in active medical use, as inhibitors like doxorubicin (anthracycline, TopII inhibitor [14] ), etoposide (TopII inhibitor [13] ), ciprofloxaxin (fluoroquinolone, TopII inhibitor [18] ), and irinotecan (camptothecin derivative, TopI inhibitor [19] ) were all included in the 2019 WHO Model List for Essential Medicines. [20]

Topoisomerase I inhibitors

Mechanism

TopI relaxes DNA supercoiling during replication and transcription. [21] [2] Under normal circumstances, TopI attacks the backbone of DNA, forming a transient TopI-DNA intermediate that allows for the rotation of the cleaved strand around the helical axis. TopI then re-ligates the cleaved strand to reestablish duplex DNA. [22] [2] Treatment with TopI inhibitors stabilizes the intermediate cleavable complex, preventing DNA re-ligation, and inducing lethal DNA strand breaks. [22] [23] Camptothecin-derived TopI inhibitors function by forming a ternary complex with TopI-DNA and are able to stack between the base pairs that flank the cleavage site due to their planar structure. [24] Normal cells have multiple DNA checkpoints that can initiate the removal of these stabilized complexes, preventing cell death. In cancer cells, however, these checkpoints are typically inactivated, making them selectively sensitive to TopI inhibitors. [22] [23] Non-camptothecins, such as indenoisoquinolines and indolocarbazoles, also associate with TopI itself, forming hydrogen bonds with residues that typically confer resistance to camptothecin. [24] Indenosioquinolines and indolocarbazoles also lack the lactone ring present in camptothecin, making them more chemically stable and less prone to hydrolysis at biological pH. [22]

Anticancer drugs

Camptothecins

Camptothecin (CPT) was first derived from the tree Camptotheca acuminata, native to southern China. [25] [10] [26] It was isolated in a United States Department of Agriculture (USDA) led search for cortisone precursors in the late 1950s and its anticancer activity explored in the early 1960s by Dr. John Hartwell and his team at the Cancer Chemotherapy National Service Center. [10] Clinical trials during the 1970s converted CPT into its sodium salt in order to increase its solubility, however, clinical trials were unsuccessful due to the compound's toxicity. [27] [28] [19] It was not until 1985 that Hsiang et al. deduced via topoisomerase relaxation assays that the anti-tumor activity of CPT was due to its TopI inhibitory activity. [29] Cushman et al. (2000) mentions that due to a lack of observed DNA unwinding in experiments involving CPT and the non-CPT TopI inhibitor indenoisoquinoline, they believed that these inhibitors likely did not function through a mechanism involving DNA intercalation. [16] This hypothesis has been disproved, as X-ray crystallography based models have allowed for the visualization of TopI inhibitor DNA intercalation. [30]

One of important structural feature of CPT is its planar pentacyclic ring and lactone ring (the E-ring). [31] The lactone ring is believed to create the active form of the drug, but it is often prone to hydrolysis, which causes a loss in function. [32] The discovery of CPT led to the synthesis of three currently FDA approved derivatives: topotecan (TPT), irinotecan, and belotecan. [19] [33] TPT is commonly used to treat ovarian and small cell lung cancer (SCLC) while irinotecan is known to improve colon cancer. [34] [19] Commonly, TPT is used in conjunction with a combination of drugs such as cyclophosphamide, doxorubicin, and vincristine. [34] It was noted that IV treatment with TPT had similar response and survival rates to oral medication. [34] Furthermore, it has been shown that TPT treatment with radiotherapy can improve survival rates of patients with brain metastases. Belotecan is a recent CPT derivative used to treat SCLC. [35] Several clinical trials on CPT derivatives such as gimatecan and silatecan continue to progress. [35] Currently, silatecan is in a phase 2 study for the treatment of gliosarcoma in adults who have not had bevacizumab treatment. [36]

Non-camptothecins

Despite the clinical success of the many CPT derivatives, they require long infusions, have low water solubility, and possess many side effects such as temporary liver dysfunction, severe diarrhea, and bone marrow damage. [28] Additionally, there has been an increase in observed single point mutations that have shown to prompt TopI resistance to CPT. [37] Therefore, three clinically relevant non-CPT inhibitors, indenoisoquinoline, phenanthridines, and indolocarbazoles, are currently being considered by the FDA as possible chemotherapies. [19] Among the non-CPT inhibitors, indolocarbazoles have shown the most promise. These inhibitors have unique advantages compared with the CPT. First, they are more chemically stable due to the absence of the lactone E-ring. [19] Second, indolocarbazoles attach to TopI at different sections of the DNA. Third, this inhibitor expresses less reversibility than CPT. [38] Therefore, they require shorter infusion times because the TopI inhibitor complex is less likely to dissociate. [19] [38] Currently, several other indolocarbazoles are also undergoing clinical trials. [39] Other than indocarbazoles, topovale (ARC-111) is considered one of the most clinically developed phenanthridine. They have been promising in fighting colon cancer, but have shown limited effectiveness against breast cancer. [40]

The first member of the indolocarbazole family of topoisomerase inhibitors, BE-13793C, was discovered in 1991 by Kojiri et al. [15] It was produced by a streptomycete similar to Streptoverticillium mobaraense, and DNA relaxation assays revealed that BE-13793C is capable of inhibiting both TopI and TopII. [15] Soon after, more indolocarbazole variants were found with TopI specificity. [41]

Cushman et al. (1978) details the discovery of the first indenoisoquinoline, indeno[1,2-c]isoquinoline (NSC 314622), which was made accidentally in an attempt to synthesize nitidine chloride, an anticancer agent that does not inhibit topoisomerases. [16] [38] [42] Research on the anticancer activity of indenoisoquinoline ceased until the late 90s as interest grew for CPT class alternatives. [16] Since then, work on developing effective derivatives has been spearheaded by researchers like Dr. Mark Cushman at Purdue University and Dr. Yves Pommier at the National Cancer Institute. [16] [43] [44] As of 2015, indotecan (LMP-400) and indimitecan (LMP-776), derivatives of indeno[1,2-c]isoquinoline, were in phase one clinical trials for the treatment of relapsed solid tumors and lymphomas. [45] [46]

Topoisomerase II inhibitors

Mechanism

TopII forms a homodimer that functions by cleaving double stranded DNA, winding a second DNA duplex through the gap, and re-ligating the strands. [2]   TopII is necessary for cell proliferation and is abundant in cancer cells, which make TopoII inhibitors effective anti-cancer treatments. [2] [23] In addition, some inhibitors, such as quinalones, fluoroquinalones and coumarins, are specific only to bacterial type 2 topoisomerases (TopoIV and gyrase), making them effective antibiotics. [47] [48] [7] Regardless of their clinical use, TopoII inhibitors are classified as either catalytic inhibitors or poisons. TopoII catalytic inhibitors bind the N-terminal ATPase subunit of TopoII, preventing the release of the separated DNA strands from the TopII dimer. [49] The mechanisms of these inhibitors are diverse. For example, ICRF-187 binds non-competitively to the N-terminal ATPase of eukaryotic TopoII, while coumarins bind competitively to the B subunit ATPase of gyrase. [7] [49] Alternatively, TopoII poisons generate lethal DNA strand breaks by either promoting the formation of covalent TopII-DNA cleavage complexes, or by inhibiting re-ligation of the cleaved strand. [23] Some poisons, such as doxorubicin, have been proposed to intercalate in the strand break between the base pairs that flank the TopII-DNA intermediate. [50] Others, such as etoposide, interact with specific amino acids in TopII to from a stable ternary complex with the TopII-DNA intermediate. [51]

Antibiotics

Aminocoumarins

Aminocoumarins (coumarins and simocyclinones) and quinolones are the two main classes of TopII inhibitors that function as antibiotics. [48] The aminocoimarins can be further divided into two groups:

  1. Traditional coumarin
  2. Simocyclioners

The coumarins group, which includes novobiocin and coumermycin, are natural products from the streptomyces species and target the bacterial enzyme DNA gyrase (TopII). [7] [48] Mechanistically,  the inhibitor binds in the B subunit of the gyrase (gyrB) and prevents ATPase activity. [52] [7] [48] This is attributed to the drug creating a stable conformation of the enzyme, which exhibits a low affinity for ATP which is needed for DNA supercoiling. [7] It is proposed that the drug functions as a competitive inhibitor. Thus, at high concentrations, ATP outcompetes the drug. [7] One limitation of traditional coumarins is gyrB ability to confer antibiotic resistance due to mutations and as a result decrease the inhibitor's ability to bind and induce cell death. [48] [53]

Simocyclinones are another class of TopII antibiotics but differ from aminocoumarins in that they are composed of both aminocoumarins and a polyketide element. They also inhibit DNA gyrase's ability to bind to DNA instead of inhibiting ATPase activity, and produces several antibiotic classes. [30] These antibiotics are further divided into two group: actinomycin A and actinomycin B. [30] It was shown that both actinomycin A and actinomycin B were highly effective in killing gram-positive bacteria. Although simocyclinones are effective antibiotics, research has shown that one strain of aimocyclioners, S. antibioticus, cause streptomyces to produce antibiotics. [54]

Quinolones

Quinolones are amongst the most commonly used antibiotics for bacterial infections in humans, and are used to treat illness such as urinary infections, skin infections, sexually transmitted diseases (STD), tuberculosis and some anthrax infections. [53] [30] [10] The effectiveness of quinolones is proposed to be from chromosome fragments, which initiate the accumulation of reactive oxygen species that leads to apoptosis. [53] Quinolones can be divided into four generations:

  1. First generation: nalidixic acid [11]
  2. Second generation: cinoxacin, norfloxacin, ciprofloxacin [11]
  3. Third generation: levofloxacin, sparfloxacin [11]
  4. Fourth generation: moxifloxacin [11]

The first quinolone was discovered in 1962 by George Lesher and his co-workers at Sterling Drug (now owned by Sanofi) as an impurity collected while manufacturing chloroquine, an antimalarial drug. [13] [55] [47] This impurity was used to develop nalidixic acid, which was made clinically available in 1964. [13] Along with its novel structure and mechanism, nalidixic acid's gram negative activity, oral application, and relatively simple synthesis (qualities common among quinolones), showed promise. [55] [11] Despite these features, it was relegated to solely treat urinary tract infections because of its small spectrum of activity. [13] [55] [11] The newer generation of drugs are classified as fluoroquinolones due to the addition of a fluorine and a methyl-piperazine, which allows for improved gyrase targeting (TopII). [10] It is proposed that this added fluorine substituent aids in base stacking during fluoroquinolone intercalation into TopII cleaved DNA by altering the electron density of the quinolone ring. [56] The first member of the fluoroquinolone subclass, norfloxacin, was discovered by Koga and colleagues at the pharmaceutical company Kyorin in 1978. [11] It was found to possess higher anti-gram negative potency than standard quinolones, and showed some anti-gram positive effects. [55] Both its blood serum levels and tissue penetration abilities proved to be poor, and it was overshadowed by the development of ciprofloxacin, a fluoroquinolone with a superior spectrum of activity. [47] Fluoroquinolones have proven to be effective on a wide array of microbial targets, with some third and fourth generation drugs possessing both anti-Gram positive and anti-anerabic capabilities. [11]

Currently, the US Food and Drug Administration (FDA) has updated the public on eight new-generation fluoroquinolones: moxifloxacin, delafloxacin, ciprofloxacin, ciprofloxacin extended-release, gemifloxacin, levofloxacin, and ofloxacin. [18] It was observed that the new fluoroquinolones can cause hypoglycemia, high blood pressure, and mental health effects such as agitation, nervousness, memory impairment and delirium. [57] [18]

Although quinolones are successful as antibiotics, their effectiveness is limited due to accumulation of small mutations and multi-drug efflux mechanisms, which pump out unwanted drugs out of the cell. [10] In particular, smaller quinolones have shown to bind with high affinity in the multi-drug efflux pump in Escherichia coli and Staphylococcus aureus . [58] [59] [19] Despite quinolones ability to target TopII, they can also inhibit TopIV based on the organisms and type of quinolone. [10] Additionally, the discovery of mutations in the gyrB region is hypothesized to cause quinolone-based antibiotic resistance. [10] [60] Specifically, the mutations from aspartate (D) to asparagine (N), and Lysine (K) to glutamic acid (E) are believed to disrupt interactions, leading to some loss of tertiary structure. [10] [60]

Mechanically, the since disproven, Shen et al. (1989) model of quinolone inhibitor binding proposed that, in each DNAgyrase-DNA complex, four quinolone molecules associate with one another via hydrophobic interactions and form hydrogen bonds with the bases of separated, single stranded segments of DNA. [11] [61] [56] Shen et al. based their hypothesis on observations regarding the increased affinity and site specificity of quinolone binding to single stranded DNA compared to relaxed double stranded DNA. [61] A modified version of the Shen et al. model was still regarded as a likely mechanism in the mid to late 2000's, [11] [62] but X-ray crystallography-based models of inhibitor-DNA-TopII complex stable intermediates developed in 2009 have since contradicted this hypothesis. [63] [56] This newer model suggests that two quinolone molecules intercalate at the two DNA nick sites created by TopII, aligning with a hypothesis proposed by Leo et al. (2005). [64] [56] [47]

Anticancer therapeutics

Intercalating poison

TopII inhibitors have two main identification: poisons and catalytic inhibitors. [65] [62] TopII poisons are characterized by their ability to create irreversible covalent bonds with DNA. [62] Furthermore, TopII poisons are divided into two groups: intercalating or non-intercalating poisons. [62] [8] The anthracycline family, one of the most medically prevalent types of intercalating poisons, are able to treat a variety of cancer due to its diverse derivations and are often prescribed in combination with other chemotherapeutic medications. [14] [62]

The first anthracycline (doxorubicin) was isolated from the bacteria Streptomyces peucetius in the 1960s. [14] [17] Anthracyclines are composed of a core of four hexane rings, the central two of which are quinone and hydroquinone rings. A ring adjacent to the hydroquinone is connected to two substituents, a daunosamine sugar and a carbonyl with a varying side chain. [17] Currently, there are four main anthracyclines in medical use:

  1. Doxorubicin
  2. Daunorubicin (doxorubicin precursor)
  3. Epirubicin (a doxorubicin stereoisomer)
  4. Idarubicin (a daunorubicin derivative) [17]

Idarubicin is able to pass through cell membranes easier than daunorubicin and doxorubicin because it possesses less polar subunits, making it more lipophilic. [17] [66] It is hypothesized that doxorubicin, which possesses a hydroxyl group and a methoxy group not present in idarubicin, can form hydrogen bonding aggregates with itself on the surface of phospholipid membranes, further reducing its ability to enter cells. [66]

Despite the success of these poisons, they have been shown that interaction poisons have a few limitations including 1) little inhibitor success of small compounds 2) anthracyclines’ adverse effects such as membrane damage and secondary cancers due to oxygen-free radical generation 3) congestive heart failure. [62] The harmful oxygen free radical generation associated with the use of doxorubicin and other anthracyclines stems, in part, from their quinone moiety undergoing redox reactions mediated by oxido-reductases, resulting in the formation of superoxide anions, hydrogen peroxide, and hydroxyl radicals. [17] [14] The mitochondrial electron transport chain pathway containing NADH hydrogenase is one potential instigator of these redox reactions. [17] The reactive oxygen species produced by interactions like this can interfere with cell signaling pathways that utilize protein kinase A, protein kinase C and calcium/calmodulin-dependent protein kinase II (CaMKII), a kinase integral in controlling calcium ion channels in cardiomyocites. [14]

Non-intercalating poisons

Another category of TopII poisons is known as non-intercalating poisons. The main non-intercalating TopII poisons are etoposide and teniposide. These non-intercalating poisons specifically target prokaryotic TopII in DNA by blocking transcription and replication. [62] Studies have shown that non-intercalating poisons play an important role in confining TopII-DNA covalent complexes. [62] Etoposide, a semi-synthetic derivative of epipodophyllotoxin is commonly used to study this apoptotic mechanism and include:

  1. Etoposide
  2. Teniposide

Both etoposide and teniposide are naturally occurring semi-synthetic derivatives of podophyllotoxins and are important anti-cancer drugs that function to inhibit TopII activity. [67] Etoposide is synthesized from podophyllum extracts found in the North American May Apple plant and the North American Mandrake plant. More specifically, Podophyllotoxins are spindle poisons that cause inhibition of mitosis by blocking mitrotubular assembly. In relation, etoposide functions to inhibit the cell cycle progression at the pre-mitotic stage (late S and G2) by breaking strands of DNA via the interaction with DNA and TopII or by the formation of free radicals. [13] [68] Etoposide has shown to be one of the most active drugs for small cell lung cancer (SCLC), testicular carcinoma and malignant lymphoma. [69] Studies have indicated that some major therapeutic activity for the drug has been found in small cell bronchogenic carcinoma, germ cell malignancies, acute non-lymphocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma. [70] Additionally, studies have shown when treated with etoposide derivatives there is an anti-leukemic dose response that differ compared to the normal hematopoietic elements. Etoposide is a highly schedule-dependent drug and is typically administered orally and recommended to take twice the dosage for effective treatment. [13] [68] However, with the selective dosage, etoposide treatment is dose limiting proposing toxic effects like myelosupressio n (leukopenia) and primarily hematologic. [13] [70] Furthermore, around 20-30% of patients who take the recommended dosage can have hematologic symptoms such as alopecia, nausea, vommitting and stomatitis. [13] Despite the side effects, etoposide has demonstrated activity in many diseases and could contribute in combination chemotherapeutic regimens for these cancer related diseases. [13]

Similarly, teniposide is another drug that helps treat leukemia. Teniposide functions very similarly to etoposide in that they are both phase specific and act during the late S and early G2 phases of the cell cycle. [71] However, teniposide is more protein-bound than etoposide. [71] Additionally, teniposide has a greater uptake, higher potency and greater binding affinity to cells compared to etoposide. Studies have shown that teniposide is an active anti-tumor agent and have been used in clinical settings to evaluate the efficacy of teniposide. [71] In a study performed by the European Organization for the Research and Treatment of Cancer (EORTC) and Lung Cancer Cooperative Group (LCCG), the results of toxicity of teniposide indicated hematologic and mild symptoms similar to etoposide. [71] However, the study found that the treatment outcome for patients with brain metastasis of SCLC had low survival and improvement rates. [71]

Mutations

Although the function of TopII poisons are not completely understood there is evidence that there is differences in structural specificity between intercalating and non-intercalating poisons. It is known that the difference between the two classifications of poisons rely on their biological activity and its role in the formation of the TopII-DNA covalent complexes. [72] More specifically, this difference occurs between the chromophore framework and the base pairs of DNA. [72] As a result of their structural specificity, slight differences in chemical amplification between antibiotics are seen. [72] Thus, this provides explanation on why theses drugs show differences in clinical activity in patients. [72]

Despite the difference in structural specificity, they both present mutations that result in anticancer drug resistance [72] In relation to intercalating poisons, it has been found that there are recurrent somatic mutations in the anthracyclines family. [73] Studies have shown that in DNA methyltransferase 3A (DNMT3A) the most frequent mutation is seen at arginine 882 (DNMT3AR882). [73] This mutation impacts patients with acute myeloid leukemia (AML) by initially responding to chemotherapy but relapsing afterwards. [73] The persistence of DNMT3AR882 cells induce hematopoietic stem cell expansion and promotes resistance to anthracycline chemotherapy. [73]

While there has not been enough research on specific mutations occurring among non-intercalating poisons, some studies have presented data regarding resistance to etoposide specifically in human leukemia cells (HL-60). [74] R. Ganapathi et al. reported that the alteration in activity of TopII as well as a reduced drug accumulation effect tumor cell resistance to epipodophyllotoxins and anthracyclines. [14] It has been proposed that the level of TopII activity is an important determination factor in drug sensitivity. [75] This study also indicated that hypophosphorylation of TopII in HL-60 cells when treated with calcium chelator (1,2-bis-(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester) resulted in a > 2-fold reduction in etoposide-induced TopII-mediated DNA cleavable complex formation. [14] Scientists have indicated that this could be a plausible relationship between etoposide drug resistance and hypophosphorylation of HL-60 cells. [14] Additionally, a study reported by Yoshihito Matsumoto et al. showed an incidence of mutation and deletion in TopIIα mRNA of etoposide and m-amsacrine (mAMSA)-resistant cell lines. [76] TopIIα showed a decrease in activity and expression and an increase of multidrug resistance protein (MRP) levels. As a result, this diminished the intracellular target to etoposide and other TopII poisons. [76] Furthermore, it was found that phosphorylation of TopIIα from the resistant cells was more hypophsophorylated compared to the parental cells as well as loss of phosphorylation sites located in the C-terminal domain. [76] Other sources have seen this same trend and have reported hyperphosphorylation of TopII in etoposide-resistant cells and that the TopIIα located in these etoposide-resistant cells have a mutation at the amino acid residues Ser861-Phe. [75]

Catalytic inhibitors

Catalytic inhibitors are the other main identification of TopII inhibitors. Common catalytic inhibitors are Bisdioxopiperazine compounds and sometimes act competitively against TopII poisons. They function to target enzymes inside the cell thus inhibiting genetic processes such as DNA replication, and chromosome dynamics. [77] Additionally, catalytic poisons can interfere with ATPase and DNA strand passageways leading to stabilization of the DNA intermediate covalent complex. [78] Because of these unique functions, research has suggested that bis(2,6-dioxopiperazines) could potentially solve issues with cardiac toxicity caused by anti-tumor antibiotics. [79] Furthermore, in preclinical and clinical settings, bis(2,6-dioxopiperazines) is used to reduce the side effects of TopII poisons. [79] Common catalytic inhibitors that target TopII are dexrazoxane, novobiocin, merbarone and anthrycycline aclarubicin.

  1. Dexrazoxane
  2. Novobiocin
  3. Merbarone
  4. Anthrycycline aclarubicin

Dexrazoxane also known as ICRF-187 is currently the only clinically approved drug used in cancer patients to target and prevent anthrycycline mediated cardiotoxicity as well as prevent tissue injuries post extravasation of anthrocyclines. [80] [81] Dexrazoxane functions to inhibit TopII and its effects on iron homeostasis regulation. [81] Dexrazoxane is a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. [82]

Novobiocin is also known as cathomycin, albamycin or streptonivicin and is an aminocoumarin antibiotic compound that functions to bind to DNA gyrase and inhibits ATPase activity. [83] It acts as a competitive inhibitor and specifically inhibits Hsp90 and TopII. [84] Novobiocin has been investigated and used in metastatic breast cancer clinical trials, non-small lung cancer cells and treatments for psoriasis when combined with nalidixic acid. Additionally, it is regularly used as a treatment for infections by gram-positive bacteria. [85] Novobiocin is derived from coumarin and the structure of novobiocin is similar to that of coumarin.

Synthetic lethality with deficient WRN expression

Synthetic lethality arises when a combination of deficiencies in the expression of two or more genes leads to cell death, whereas a deficiency in expression of only one of these genes does not. The deficiencies can arise through mutations, epigenetic alterations or inhibitors of the genes. Synthetic lethality with the topoisomerase inhibitor irinotecan appears to occur when given to cancer patients with deficient expression of the DNA repair gene WRN .[ citation needed ]

The analysis of 630 human primary tumors in 11 tissues shows that hypermethylation of the WRN CpG island promoter (with loss of expression of WRN protein) is a common event in tumorigenesis. [86] WRN is repressed in about 38% of colorectal cancers and non-small-cell lung carcinomas and in about 20% or so of stomach cancers, prostate cancers, breast cancers, non-Hodgkin lymphomas and chondrosarcomas, plus at significant levels in the other cancers evaluated. The WRN protein helicase is important in homologous recombinational DNA repair and also has roles in non-homologous end joining DNA repair and base excision DNA repair. [87]

A 2006 retrospective study, with long clinical follow-up, was made of colon cancer patients treated with the topoisomerase inhibitor irinotecan. In this study, 45 patients had hypermethylated WRN gene promoters and 43 patients had unmethylated WRN promoters. [86] Irinotecan was more strongly beneficial for patients with hypermethylated WRN promoters (39.4 months survival) than for those with unmethylated WRN promoters (20.7 months survival). Thus, a topoisomerase inhibitor appeared to be especially synthetically lethal with deficient WRN expression. Further evaluations have also indicated synthetic lethality of deficient expression of WRN and topoisomerase inhibitors. [88] [89] [90] [91] [92]

Related Research Articles

Nalidixic acid

Nalidixic acid is the first of the synthetic quinolone antibiotics.

Doxorubicin Chemotherapy medication

Doxorubicin, sold under the brand name Adriamycin among others, is a chemotherapy medication used to treat cancer. This includes breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. It is often used together with other chemotherapy agents. Doxorubicin is given by injection into a vein.

Daunorubicin

Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. It is used by injection into a vein. A liposomal formulation known as liposomal daunorubicin also exists.

Anthracycline

Anthracyclines is a class of drugs used in cancer chemotherapy that are extracted from Streptomyces bacterium. These compounds are used to treat many cancers, including leukemias, lymphomas, breast, stomach, uterine, ovarian, bladder cancer, and lung cancers. The first anthracycline discovered was daunorubicin, which is produced naturally by Streptomyces peucetius, a species of actinobacteria. Clinically the most important anthracyclines are doxorubicin, daunorubicin, epirubicin and idarubicin.

Etoposide

Etoposide, sold under the brand name Vepesid among others, is a chemotherapy medication used for the treatments of a number of types of cancer including testicular cancer, lung cancer, lymphoma, leukemia, neuroblastoma, and ovarian cancer. It is also used for hemophagocytic lymphohistiocytosis. It is used by mouth or injection into a vein.

Mitoxantrone

Mitoxantrone is an anthracenedione antineoplastic agent.

Teniposide

Teniposide is a chemotherapeutic medication used in the treatment of childhood acute lymphocytic leukemia (ALL), Hodgkin's lymphoma, certain brain tumours, and other types of cancer. It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body.

Topotecan

Topotecan, sold under the brand name Hycamtin among others, is a chemotherapeutic agent medication that is a topoisomerase inhibitor. It is a synthetic, water-soluble analog of the natural chemical compound camptothecin. It is used in the form of its hydrochloride salt to treat ovarian cancer, lung cancer and other cancer types.

Genistein Chemical compound

Genistein (C15H10O5) is a naturally occurring compound that structurally belongs to a class of compounds known as isoflavones. It is described as an angiogenesis inhibitor and a phytoestrogen.

Pefloxacin

Pefloxacin is a quinolone antibiotic used to treat bacterial infections. Pefloxacin has not been approved for use in the United States.

Amsacrine

Amsacrine is an antineoplastic agent.

Type I topoisomerase

In molecular biology Type I topoisomerases are enzymes that cut one of the two strands of double-stranded DNA, relax the strand, and reanneal the strand. They are further subdivided into two structurally and mechanistically distinct topoisomerases: type IA and type IB.

Type II topoisomerase

Type II topoisomerases are topoisomerases that cut both strands of the DNA helix simultaneously in order to manage DNA tangles and supercoils. They use the hydrolysis of ATP, unlike Type I topoisomerase. In this process, these enzymes change the linking number of circular DNA by ±2.

TOP2A

DNA topoisomerase 2-alpha is an enzyme that in humans is encoded by the TOP2A gene.

Camptothecin

Camptothecin (CPT) is a topoisomerase poison. It was discovered in 1966 by M. E. Wall and M. C. Wani in systematic screening of natural products for anticancer drugs. It was isolated from the bark and stem of Camptotheca acuminata, a tree native to China used as a cancer treatment in Traditional Chinese Medicine. It has been used clinically more recently in China for the treatment of gastrointestinal tumors.CPT showed remarkable anticancer activity in preliminary clinical trials especially against breast, ovarian, colon, lung, and stomach cancers However, it has low solubility and adverse effects have been reported when used therapeutically, so synthetic and medicinal chemists have developed numerous syntheses of camptothecin and various derivatives to increase the benefits of the chemical, with good results. Four CPT analogues have been approved and are used in cancer chemotherapy today, topotecan, irinotecan, belotecan, and trastuzumab deruxtecan. Camptothecin has also been found in other plants including Chonemorpha fragrans. In addition to being a anti-tumor agent, Camptothecin has also shown anti-HIV activity because it interrupts self-association of the viral-infectivity factor found in many retroviruses including HIV

TOP1 DNA topoisomerase enzyme

DNA topoisomerase 1 is an enzyme that in humans is encoded by the TOP1 gene. It is a DNA topoisomerase, an enzyme that catalyzes the transient breaking and rejoining of a single strand of DNA.

Flumequine

Flumequine is a synthetic fluoroquinolone antibiotic used to treat bacterial infections. It is a first-generation fluoroquinolone antibacterial that has been removed from clinical use and is no longer being marketed. The marketing authorization of flumequine has been suspended throughout the EU. It kills bacteria by interfering with the enzymes that cause DNA to unwind and duplicate. Flumequine was used in veterinarian medicine for the treatment of enteric infections, as well as to treat cattle, swine, chickens, and fish, but only in a limited number of countries. It was occasionally used in France to treat urinary tract infections under the trade name Apurone. However this was a limited indication because only minimal serum levels were achieved.

Synthetic lethality arises when a combination of deficiencies in the expression of two or more genes leads to cell death, whereas a deficiency in only one of these genes does not. The deficiencies can arise through mutations, epigenetic alterations or inhibitors of one of the genes. In a synthetic lethal genetic screen, it is necessary to begin with a mutation that does not kill the cell, although may confer a phenotype, and then systematically test other mutations at additional loci to determine which confer lethality. Synthetic lethality has utility for purposes of molecular targeted cancer therapy, with the first example of a molecular targeted therapeutic exploiting a synthetic lethal exposed by an inactivated tumor suppressor gene receiving FDA approval in 2016. A sub-case of synthetic lethality, where vulnerabilities are exposed by the deletion of passenger genes rather than tumor suppressor is the so-called "collateral lethality".

HU-331 Chemical compound

HU-331 is a quinone anticarcinogenic drug synthesized from cannabidiol, a cannabinoid in the Cannabis sativa plant. It showed a great efficacy against oncogenic human cells. HU-331 does not cause arrest in cell cycle, cell apoptosis or caspase activation. HU-331 inhibits DNA topoisomerase II even at nanomolar concentrations, but has shown a negligible effect on the action of DNA topoisomerase I. The cannabinoid quinone HU-331 is a very specific inhibitor of topoisomerase II, compared with most known anticancer quinones. One of the main objectives of these studies is the development of a new quinone derived compound that produces anti-neoplastic activity while maintaining low toxicity at therapeutic doses.

Ellipticine Chemical compound

Ellipticine is an alkaloid first extracted from trees of the species Ochrosia elliptica and Rauvolfia sandwicensis, which inhibits the enzyme topoisomerase II via intercalative binding to DNA.

References

  1. 1 2 Cooper, Geoffrey M. (2019). The Cell: A Molecular Approach Eighth Edition. Oxford University Press. p. 222. ISBN   9781605357072.
  2. 1 2 3 4 5 6 7 Nelson, David L.; Cox, Michael M. (2017). Lehninger Principles of Biochemistry Seventh Edition. W. H. Freeman and Company. pp. 963–971. ISBN   9781464126116.
  3. 1 2 3 4 5 Delgado, Justine L.; Hsieh, Chao-Ming; Chan, Nei-Li; Hiasa, Hiroshi (2018-01-31). "Topoisomerases as anticancer targets". Biochemical Journal. 475 (2): 373–398. doi:10.1042/BCJ20160583. ISSN   0264-6021. PMC   6110615 . PMID   29363591.
  4. Waksman, Selman A.; Woodruff, H. Boyd (1940). "The Soil as a Source of Microorganisms Antagonistic to Disease-Producing Bacteria*1". Journal of Bacteriology. 40 (4): 581–600. doi:10.1128/jb.40.4.581-600.1940. ISSN   0021-9193. PMC   374661 . PMID   16560371.
  5. Bush, Karen (December 2010). "The coming of age of antibiotics: discovery and therapeutic value: Origins of antibiotic drug discovery". Annals of the New York Academy of Sciences. 1213 (1): 1–4. doi:10.1111/j.1749-6632.2010.05872.x. PMID   21175674. S2CID   205935691.
  6. Chevrette, Marc G.; Currie, Cameron R. (March 2019). "Emerging evolutionary paradigms in antibiotic discovery". Journal of Industrial Microbiology & Biotechnology. 46 (3–4): 257–271. doi:10.1007/s10295-018-2085-6. ISSN   1367-5435. PMID   30269177. S2CID   52889274.
  7. 1 2 3 4 5 6 7 Di Marco, A.; Cassinelli, G.; Arcamone, F. (1981). "The discovery of daunorubicin". Cancer Treatment Reports. 65 Suppl 4: 3–8. ISSN   0361-5960. PMID   7049379.
  8. 1 2 Marinello, Jessica; Delcuratolo, Maria; Capranico, Giovanni (2018-11-06). "Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives". International Journal of Molecular Sciences. 19 (11): 3480. doi:10.3390/ijms19113480. ISSN   1422-0067. PMC   6275052 . PMID   30404148.
  9. Buzun, Kamila; Bielawska, Anna; Bielawski, Krzysztof; Gornowicz, Agnieszka (2020-01-01). "DNA topoisomerases as molecular targets for anticancer drugs". Journal of Enzyme Inhibition and Medicinal Chemistry. 35 (1): 1781–1799. doi:10.1080/14756366.2020.1821676. ISSN   1475-6366. PMC   7534307 . PMID   32975138.
  10. 1 2 3 4 5 6 7 8 9 10 11 Wall, Monroe E. (1998). "Camptothecin and taxol: Discovery to clinic". Medicinal Research Reviews. 18 (5): 299–314. doi:10.1002/(SICI)1098-1128(199809)18:5<299::AID-MED2>3.0.CO;2-O. ISSN   1098-1128. PMID   9735871.
  11. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Mitscher, Lester A. (2005-06-14). "Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents". ChemInform. 36 (24): 559–92. doi:10.1002/chin.200524274. ISSN   0931-7597. PMID   15700957.
  12. Gellert, M.; Mizuuchi, K.; O'Dea, M. H.; Nash, H. A. (1976-11-01). "DNA gyrase: an enzyme that introduces superhelical turns into DNA". Proceedings of the National Academy of Sciences. 73 (11): 3872–3876. Bibcode:1976PNAS...73.3872G. doi:10.1073/pnas.73.11.3872. ISSN   0027-8424. PMC   431247 . PMID   186775.
  13. 1 2 3 4 5 6 7 8 9 10 Sinkule, J. A. (March 1984). "Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent". Pharmacotherapy. 4 (2): 61–73. doi:10.1002/j.1875-9114.1984.tb03318.x. ISSN   0277-0008. PMID   6326063. S2CID   31424235.
  14. 1 2 3 4 5 6 7 8 9 Benjanuwattra, Juthipong; Siri-Angkul, Natthaphat; Chattipakorn, Siriporn C.; Chattipakorn, Nipon (January 2020). "Doxorubicin and its proarrhythmic effects: A comprehensive review of the evidence from experimental and clinical studies". Pharmacological Research. 151: 104542. doi:10.1016/j.phrs.2019.104542. PMID   31730804.
  15. 1 2 3 Kojiri, Katsuhisa; Kondo, Hisao; Yoshinari, Tomoko; Arakawa, Hiroharu; Nakajima, Shigeru; Satoh, Fumio; Kawamura, Kenji; Okura, Akira; Suda, Hiroyuki; Okanishi, Masanori (1991). "A new antitumor substance, BE-13793C, produced by a streptomycete. Taxonomy, fermentation, isolation, structure determination and biological activity". The Journal of Antibiotics. 44 (7): 723–728. doi: 10.7164/antibiotics.44.723 . ISSN   0021-8820. PMID   1652582.
  16. 1 2 3 4 5 6 Cushman, Mark; Jayaraman, Muthusamy; Vroman, Jeffrey A.; Fukunaga, Anna K.; Fox, Brian M.; Kohlhagen, Glenda; Strumberg, Dirk; Pommier, Yves (October 2000). "Synthesis of New Indeno[1,2- c ]isoquinolines: Cytotoxic Non-Camptothecin Topoisomerase I Inhibitors". Journal of Medicinal Chemistry. 43 (20): 3688–3698. doi:10.1021/jm000029d. ISSN   0022-2623. PMID   11020283.
  17. 1 2 3 4 5 6 7 McGowan, John V; Chung, Robin; Maulik, Angshuman; Piotrowska, Izabela; Walker, J Malcolm; Yellon, Derek M (February 2017). "Anthracycline Chemotherapy and Cardiotoxicity". Cardiovascular Drugs and Therapy. 31 (1): 63–75. doi:10.1007/s10557-016-6711-0. ISSN   0920-3206. PMC   5346598 . PMID   28185035.
  18. 1 2 3 Research, Center for Drug Evaluation and (2019-04-15). "FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes". FDA.
  19. 1 2 3 4 5 6 7 8 Li, Fengzhi; Jiang, Tao; Li, Qingyong; Ling, Xiang (2017-12-01). "Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?". American Journal of Cancer Research. 7 (12): 2350–2394. ISSN   2156-6976. PMC   5752681 . PMID   29312794.
  20. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
  21. Sinha, Birandra K. (1995-01-01). "Topoisomerase Inhibitors". Drugs. 49 (1): 11–19. doi:10.2165/00003495-199549010-00002. ISSN   1179-1950. PMID   7705211. S2CID   46985043.
  22. 1 2 3 4 Pommier, Yves (2009-07-08). "DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition". Chemical Reviews. 109 (7): 2894–2902. doi:10.1021/cr900097c. ISSN   0009-2665. PMC   2707511 . PMID   19476377.
  23. 1 2 3 4 Pommier, Yves; Leo, Elisabetta; Zhang, Hongliang; Marchand, Christophe (2010-05-28). "DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs". Chemistry & Biology. 17 (5): 421–433. doi:10.1016/j.chembiol.2010.04.012. ISSN   1074-5521. PMC   7316379 . PMID   20534341.
  24. 1 2 Pommier, Yves (October 2006). "Topoisomerase I inhibitors: camptothecins and beyond". Nature Reviews Cancer. 6 (10): 789–802. doi:10.1038/nrc1977. ISSN   1474-1768. PMID   16990856. S2CID   25135019.
  25. Perdue, Robert E.; Smith, Robert L.; Wall, Monroe E.; Hartwell, Jonathan L.; Abbott, Betty J.; Perdue, Robert E.; Smith, Robert L.; Wall, Monroe E.; Hartwell, Jonathan L.; Abbott, Betty J. (1970). "Camptotheca acuminata Decaisne (Nyssaceae) Source of Camptothecin, an Antileukemic Alkaloid". doi:10.22004/AG.ECON.171841.Cite journal requires |journal= (help)
  26. D'yakonov, Vladimir A.; Dzhemileva, Lilya U.; Dzhemilev, Usein M. (2017), "Advances in the Chemistry of Natural and Semisynthetic Topoisomerase I/II Inhibitors", Studies in Natural Products Chemistry, Elsevier, 54, pp. 21–86, doi:10.1016/b978-0-444-63929-5.00002-4, ISBN   978-0-444-63929-5 , retrieved 2020-12-20
  27. Liu, Ying-Qian; Li, Wen-Qun; Morris‐Natschke, Susan L.; Qian, Keduo; Yang, Liu; Zhu, Gao-Xiang; Wu, Xiao-Bing; Chen, An-Liang; Zhang, Shao-Yong; Nan, Xiang; Lee, Kuo-Hsiung (2015). "Perspectives on Biologically Active Camptothecin Derivatives". Medicinal Research Reviews. 35 (4): 753–789. doi:10.1002/med.21342. ISSN   1098-1128. PMC   4465867 . PMID   25808858.
  28. 1 2 Cunha, Kênya Silva; Reguly, Maria Luíza; Graf, Ulrich; Rodrigues de Andrade, Heloisa Helena (2002-03-01). "Comparison of camptothecin derivatives presently in clinical trials: genotoxic potency and mitotic recombination". Mutagenesis. 17 (2): 141–147. doi: 10.1093/mutage/17.2.141 . ISSN   0267-8357. PMID   11880543.
  29. Hsiang, Y. H.; Hertzberg, R.; Hecht, S.; Liu, L. F. (1985-11-25). "Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I". The Journal of Biological Chemistry. 260 (27): 14873–14878. doi:10.1016/S0021-9258(17)38654-4. ISSN   0021-9258. PMID   2997227.
  30. 1 2 3 4 Staker, Bart L.; Feese, Michael D.; Cushman, Mark; Pommier, Yves; Zembower, David; Stewart, Lance; Burgin, Alex B. (April 2005). "Structures of Three Classes of Anticancer Agents Bound to the Human Topoisomerase I−DNA Covalent Complex". Journal of Medicinal Chemistry. 48 (7): 2336–2345. doi:10.1021/jm049146p. ISSN   0022-2623. PMID   15801827.
  31. Lu, Ai-jun; Zhang, Zhen-shan; Zheng, Ming-yue; Zou, Han-jun; Luo, Xiao-min; Jiang, Hua-liang (February 2007). "3D-QSAR study of 20 ( S )-camptothecin analogs". Acta Pharmacologica Sinica. 28 (2): 307–314. doi: 10.1111/j.1745-7254.2007.00477.x . ISSN   1745-7254. PMID   17241535. S2CID   25448878.
  32. Ulukan, Hulya; Swaan, Peter W. (2002-10-01). "Camptothecins". Drugs. 62 (14): 2039–2057. doi:10.2165/00003495-200262140-00004. ISSN   1179-1950. PMID   12269849.
  33. HOPKINS, R. P. (1983-12-01). "Principles of Biochemistry, Seventh Edition (two volumes): General Aspects, Mammalian Biochemistry". Biochemical Society Transactions. 11 (6): 829–830. doi:10.1042/bst0110829a. ISSN   0300-5127.
  34. 1 2 3 Lynch, T (1996-12-01). "Topotecan today". Journal of Clinical Oncology. 14 (12): 3053–3055. doi:10.1200/JCO.1996.14.12.3053. ISSN   0732-183X. PMID   8955649.
  35. 1 2 Hu, Guohua; Zekria, David; Cai, Xun; Ni, Xiaoling (June 2015). "Current status of CPT and its analogues in the treatment of malignancies". Phytochemistry Reviews. 14 (3): 429–441. doi:10.1007/s11101-015-9397-1. ISSN   1568-7767. S2CID   14747493.
  36. Arno Therapeutics (2014-12-08). "A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma".Cite journal requires |journal= (help)
  37. Pommier, Yves; Pourquier, Philippe; Urasaki, Yoshimasa; Wu, Jiaxi; Laco, Gary S. (October 1999). "Topoisomerase I inhibitors: selectivity and cellular resistance". Drug Resistance Updates. 2 (5): 307–318. doi:10.1054/drup.1999.0102. ISSN   1368-7646. PMID   11504505.
  38. 1 2 3 Cushman, Mark; Cheng, Leung (September 1978). "Stereoselective oxidation by thionyl chloride leading to the indeno[1,2-c]isoquinoline system". The Journal of Organic Chemistry. 43 (19): 3781–3783. doi:10.1021/jo00413a036. ISSN   0022-3263.
  39. Long, Byron H.; Rose, William C.; Vyas, Dolatrai M.; Matson, James A.; Forenza, Salvatore (March 2002). "Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles". Current Medicinal Chemistry. Anti-Cancer Agents. 2 (2): 255–266. doi:10.2174/1568011023354218. ISSN   1568-0118. PMID   12678746.
  40. Li, Tsai-Kun; Houghton, Peter J.; Desai, Shyamal D.; Daroui, Parima; Liu, Angela A.; Hars, Eszter S.; Ruchelman, Alexander L.; LaVoie, Edmond J.; Liu, Leroy F. (2003-12-01). "Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug". Cancer Research. 63 (23): 8400–8407. ISSN   0008-5472. PMID   14679002.
  41. Yamashita, Yoshinori; Fujii, Noboru; Murakata, Chikara; Ashizawa, Tadashi; Okabe, Masami; Nakano, Hirofumi (1992-12-08). "Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives". Biochemistry. 31 (48): 12069–12075. doi:10.1021/bi00163a015. ISSN   0006-2960. PMID   1333791.
  42. Cui, Yue; Wu, Linhui; Cao, Ruoxue; Xu, Hui; Xia, Jun; Wang, Z Peter; Ma, Jia (2020). "Antitumor functions and mechanisms of nitidine chloride in human cancers". Journal of Cancer. 11 (5): 1250–1256. doi:10.7150/jca.37890. ISSN   1837-9664. PMC   6959075 . PMID   31956371.
  43. Huang, Chia-Yu; Kavala, Veerababurao; Kuo, Chun-Wei; Konala, Ashok; Yang, Tang-Hao; Yao, Ching-Fa (2017-02-17). "Synthesis of Biologically Active Indenoisoquinoline Derivatives via a One-Pot Copper(II)-Catalyzed Tandem Reaction". The Journal of Organic Chemistry. 82 (4): 1961–1968. doi:10.1021/acs.joc.6b02814. ISSN   0022-3263. PMID   28177250.
  44. "Yves Pommier, M.D., Ph.D." Center for Cancer Research. 2014-08-12. Retrieved 2020-12-13.
  45. Xu, Yang; Her, Chengtao (2015-07-22). "Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy". Biomolecules. 5 (3): 1652–1670. doi:10.3390/biom5031652. ISSN   2218-273X. PMC   4598769 . PMID   26287259.
  46. http://clinicaltrials.gov/ct2/show/NCT01051635%5B%5D
  47. 1 2 3 4 Aldred, Katie J.; Kerns, Robert J.; Osheroff, Neil (2014-03-18). "Mechanism of Quinolone Action and Resistance". Biochemistry. 53 (10): 1565–1574. doi:10.1021/bi5000564. ISSN   0006-2960. PMC   3985860 . PMID   24576155.
  48. 1 2 3 4 5 Hevener, KirkE.; Verstak, Tatsiana A.; Lutat, Katie E.; Riggsbee, Daniel L.; Mooney, Jeremiah W. (October 2018). "Recent developments in topoisomerase-targeted cancer chemotherapy". Acta Pharmaceutica Sinica. B. 8 (6): 844–861. doi:10.1016/j.apsb.2018.07.008. ISSN   2211-3835. PMC   6251812 . PMID   30505655.
  49. 1 2 Classen, Scott; Olland, Stephane; Berger, James M. (2003-09-16). "Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187". Proceedings of the National Academy of Sciences. 100 (19): 10629–10634. Bibcode:2003PNAS..10010629C. doi:10.1073/pnas.1832879100. ISSN   0027-8424. PMC   196855 . PMID   12963818.
  50. Thorn, Caroline F.; Oshiro, Connie; Marsh, Sharon; Hernandez-Boussard, Tina; McLeod, Howard; Klein, Teri E.; Altman, Russ B. (July 2011). "Doxorubicin pathways: pharmacodynamics and adverse effects". Pharmacogenetics and Genomics. 21 (7): 440–446. doi:10.1097/FPC.0b013e32833ffb56. ISSN   1744-6872. PMC   3116111 . PMID   21048526.
  51. Montecucco, Alessandra; Zanetta, Francesca; Biamonti, Giuseppe (2015-01-19). "Molecular mechanisms of etoposide". EXCLI Journal. 14: 95–108. doi:10.17179/excli2014-561. ISSN   1611-2156. PMC   4652635 . PMID   26600742.
  52. Lewis, R J; Singh, O M; Smith, C V; Skarzynski, T; Maxwell, A; Wonacott, A J; Wigley, D B (1996-03-15). "The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography". The EMBO Journal. 15 (6): 1412–1420. doi:10.1002/j.1460-2075.1996.tb00483.x. ISSN   0261-4189. PMC   450046 . PMID   8635474.
  53. 1 2 3 Anderson, V. E.; Osheroff, N. (March 2001). "Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde". Current Pharmaceutical Design. 7 (5): 337–353. doi:10.2174/1381612013398013. ISSN   1381-6128. PMID   11254893.
  54. Li, Wang; Nihira, Takuya; Sakuda, Shohei; Nishida, Takuo; Yamada, Yasuhiro (1992-01-01). "New inducing factors for virginiamycin production from Streptomyces antibioticus". Journal of Fermentation and Bioengineering. 74 (4): 214–217. doi:10.1016/0922-338X(92)90112-8. ISSN   0922-338X.
  55. 1 2 3 4 Li, Qun; Mitscher, Lester A.; Shen, Linus L. (2000). "The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors". Medicinal Research Reviews. 20 (4): 231–293. doi:10.1002/1098-1128(200007)20:4<231::AID-MED1>3.0.CO;2-N. ISSN   1098-1128. PMID   10861727.
  56. 1 2 3 4 Laponogov, Ivan; Sohi, Maninder K; Veselkov, Dennis A; Pan, Xiao-Su; Sawhney, Ritica; Thompson, Andrew W; McAuley, Katherine E; Fisher, L Mark; Sanderson, Mark R (June 2009). "Structural insight into the quinolone–DNA cleavage complex of type IIA topoisomerases". Nature Structural & Molecular Biology. 16 (6): 667–669. doi:10.1038/nsmb.1604. ISSN   1545-9993. PMID   19448616. S2CID   23776629.
  57. Wolfson, John S.; Hooper, David C. (1991-12-30). "Overview of fluoroquinolone safety". The American Journal of Medicine. Fluoroquinolones in the Treatment of Human Infection: The Role of Temafloxacin. 91 (6, Supplement 1): S153–S161. doi:10.1016/0002-9343(91)90330-Z. ISSN   0002-9343. PMID   1767803.
  58. Collin, Frédéric; Karkare, Shantanu; Maxwell, Anthony (November 2011). "Exploiting bacterial DNA gyrase as a drug target: current state and perspectives". Applied Microbiology and Biotechnology. 92 (3): 479–497. doi:10.1007/s00253-011-3557-z. ISSN   0175-7598. PMC   3189412 . PMID   21904817.
  59. Drlica, Karl; Hiasa, Hiroshi; Kerns, Robert; Malik, Muhammad; Mustaev, Arkady; Zhao, Xilin (August 2009). "Quinolones: Action and Resistance Updated". Current Topics in Medicinal Chemistry. 9 (11): 981–998. doi:10.2174/156802609789630947. ISSN   1568-0266. PMC   3182077 . PMID   19747119.
  60. 1 2 Yoshida, H.; Bogaki, M.; Nakamura, M.; Yamanaka, L. M.; Nakamura, S. (1991-08-01). "Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli". Antimicrobial Agents and Chemotherapy. 35 (8): 1647–1650. doi:10.1128/AAC.35.8.1647. ISSN   0066-4804. PMC   245234 . PMID   1656869.
  61. 1 2 Shen, Linus L.; Mitscher, Lester A.; Sharma, Padam N.; O'Donnell, T. J.; Chu, Daniel W. T.; Cooper, Curt S.; Rosen, Terry; Pernet, Andre G. (1989-05-02). "Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model". Biochemistry. 28 (9): 3886–3894. doi:10.1021/bi00435a039. ISSN   0006-2960. PMID   2546585.
  62. 1 2 3 4 5 6 7 8 Nitiss, John L. (May 2009). "Targeting DNA topoisomerase II in cancer chemotherapy". Nature Reviews. Cancer. 9 (5): 338–350. doi:10.1038/nrc2607. ISSN   1474-175X. PMC   2748742 . PMID   19377506.
  63. Wohlkonig, Alexandre; Chan, Pan F; Fosberry, Andrew P; Homes, Paul; Huang, Jianzhong; Kranz, Michael; Leydon, Vaughan R; Miles, Timothy J; Pearson, Neil D; Perera, Rajika L; Shillings, Anthony J (2010-08-29). "Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance". Nature Structural & Molecular Biology. 17 (9): 1152–1153. doi:10.1038/nsmb.1892. ISSN   1545-9993. PMID   20802486. S2CID   24498996.
  64. Leo, Elisabetta; Gould, Katherine A.; Pan, Xiao-Su; Capranico, Giovanni; Sanderson, Mark R.; Palumbo, Manlio; Fisher, L. Mark (2005-01-18). "Novel Symmetric and Asymmetric DNA Scission Determinants forStreptococcus pneumoniaeTopoisomerase IV and Gyrase Are Clustered at the DNA Breakage Site". Journal of Biological Chemistry. 280 (14): 14252–14263. doi: 10.1074/jbc.m500156200 . ISSN   0021-9258. PMID   15659402. S2CID   29092424.
  65. Atwal, Mandeep; Swan, Rebecca L.; Rowe, Chloe; Lee, Ka C.; Lee, David C.; Armstrong, Lyle; Cowell, Ian G.; Austin, Caroline A. (October 2019). "Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations". Molecular Pharmacology. 96 (4): 475–484. doi:10.1124/mol.119.117259. ISSN   0026-895X. PMC   6744389 . PMID   31399497.
  66. 1 2 Matyszewska, Dorota; Nazaruk, Ewa; Campbell, Richard A. (January 2021). "Interactions of anticancer drugs doxorubicin and idarubicin with lipid monolayers: New insight into the composition, structure and morphology". Journal of Colloid and Interface Science. 581 (Pt A): 403–416. Bibcode:2021JCIS..581..403M. doi: 10.1016/j.jcis.2020.07.092 . PMID   32771749.
  67. Imbert, T. F. (March 1998). "Discovery of podophyllotoxins". Biochimie. 80 (3): 207–222. doi:10.1016/s0300-9084(98)80004-7. ISSN   0300-9084. PMID   9615861.
  68. 1 2 Clark, Peter I.; Slevin, Maurice L. (1987-04-01). "The Clinical Pharmacology of Etoposide and Teniposide". Clinical Pharmacokinetics. 12 (4): 223–252. doi:10.2165/00003088-198712040-00001. ISSN   1179-1926. PMID   3297462. S2CID   33161084.
  69. "Food and Drug Administration (FDA)", SpringerReference, Berlin/Heidelberg: Springer-Verlag, 2011, doi:10.1007/springerreference_32222 , retrieved 2020-12-13
  70. 1 2 Vogelzang, N. J.; Raghavan, D.; Kennedy, B. J. (January 1982). "VP-16-213 (etoposide): the mandrake root from Issyk-Kul". The American Journal of Medicine. 72 (1): 136–144. doi:10.1016/0002-9343(82)90600-3. ISSN   0002-9343. PMID   6277188.
  71. 1 2 3 4 5 Postmus, Haaxma-Reiche, Smit, Groen, Karnicka, Lewinski, Meerbeeck, Clerico, Gregor, Curran, Sahmoud, Kirkpatrick, and Giaccone, Pieter E., Hanny, Egbert, Groen, Hanna, Tadeusz, Jan van, Mario, Anna, Desmond, Tarek, Anne, and Giuseppe (2000). "Treatment of Brain Metastases of Small-Cell Lung Cancer: Comparing Teniposide and Teniposide With Whole-Brain Radiotherapy—A Phase III Study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group". Journal of Clinical Oncology. 18 (19 (October 1)): 3400–3408. doi:10.1200/JCO.2000.18.19.3400. PMID   11013281.CS1 maint: multiple names: authors list (link)
  72. 1 2 3 4 5 Manfait, M.; Chourpa, I.; Sokolov, K.; Morjani, H.; Riou, J.-F.; Lavelle, F.; Nabiev, I. (1993), Theophanides, Theophile; Anastassopoulou, Jane; Fotopoulos, Nikolaos (eds.), "Intercalating and Non-Intercalating Antitumor Drugs: Structure-Function Correlations as Probed by Surface-Enhanced Raman Spectroscopy", Fifth International Conference on the Spectroscopy of Biological Molecules, Dordrecht: Springer Netherlands, pp. 59–64, doi:10.1007/978-94-011-1934-4_18, ISBN   978-94-011-1934-4 , retrieved 2020-12-15
  73. 1 2 3 4 Guryanova, Olga A.; Shank, Kaitlyn; Spitzer, Barbara; Luciani, Luisa; Koche, Richard P.; Garrett-Bakelman, Francine E.; Ganzel, Chezi; Durham, Benjamin H.; Mohanty, Abhinita; Hoermann, Gregor; Rivera, Sharon A. (December 2016). "DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling". Nature Medicine. 22 (12): 1488–1495. doi:10.1038/nm.4210. ISSN   1546-170X. PMC   5359771 . PMID   27841873.
  74. Ganapathi, R.; Constantinou, A.; Kamath, N.; Dubyak, G.; Grabowski, D.; Krivacic, K. (1996-08-01). "Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides". Molecular Pharmacology. 50 (2): 243–248. ISSN   0026-895X. PMID   8700130.
  75. 1 2 Ganapathi, Ram N.; Ganapathi, Mahrukh K. (2013-08-01). "Mechanisms regulating resistance to inhibitors of topoisomerase II". Frontiers in Pharmacology. 4: 89. doi:10.3389/fphar.2013.00089. ISSN   1663-9812. PMC   3729981 . PMID   23914174.
  76. 1 2 3 Matsumoto, Yoshihito; Takano, Hiroshi; Kunishio, Katsuzo; Nagao, Seigo; Fojo, Tito (2001). "Incidence of Mutation and Deletion in Topoisomerase IIα mRNA of Etoposide and mAMSA–resistant Cell Lines". Japanese Journal of Cancer Research. 92 (10): 1133–1137. doi:10.1111/j.1349-7006.2001.tb01069.x. ISSN   1349-7006. PMC   5926608 . PMID   11676865.
  77. Andoh, Toshiwo; Ishida, Ryoji (1998-10-01). "Catalytic inhibitors of DNA topoisomerase II". Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1400 (1): 155–171. doi:10.1016/S0167-4781(98)00133-X. ISSN   0167-4781. PMID   9748552.
  78. Kerrigan, D.; Pommier, Y.; Kohn, K. W. (1987). "Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity". NCI Monographs (4): 117–121. ISSN   0893-2751. PMID   3041238.
  79. 1 2 Andoh, T. (March 1998). "Bis(2,6-dioxopiperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs". Biochimie. 80 (3): 235–246. doi:10.1016/s0300-9084(98)80006-0. ISSN   0300-9084. PMID   9615863.
  80. Langer, Seppo W (2014-09-15). "Dexrazoxane for the treatment of chemotherapy-related side effects". Cancer Management and Research. 6: 357–363. doi:10.2147/CMAR.S47238. ISSN   1179-1322. PMC   4168851 . PMID   25246808.
  81. 1 2 Weiss, G.; Loyevsky, M.; Gordeuk, V. R. (January 1999). "Dexrazoxane (ICRF-187)". General Pharmacology. 32 (1): 155–158. doi:10.1016/s0306-3623(98)00100-1. ISSN   0306-3623. PMID   9888268.
  82. PubChem. "Dexrazoxane". pubchem.ncbi.nlm.nih.gov. Retrieved 2020-12-10.
  83. "Novobiocin". go.drugbank.com. Retrieved 2020-12-10.
  84. "NCATS Inxight: Drugs — NOVOBIOCIN". drugs.ncats.io. Retrieved 2020-12-10.
  85. PubChem. "Novobiocin". pubchem.ncbi.nlm.nih.gov. Retrieved 2020-12-10.
  86. 1 2 Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF, Herranz M, Paz MF, Sanchez-Cespedes M, Artiga MJ, Guerrero D, Castells A, von Kobbe C, Bohr VA, Esteller M (2006). "Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer". Proc. Natl. Acad. Sci. U.S.A. 103 (23): 8822–7. Bibcode:2006PNAS..103.8822A. doi:10.1073/pnas.0600645103. PMC   1466544 . PMID   16723399.
  87. Monnat RJ (2010). "Human RECQ helicases: roles in DNA metabolism, mutagenesis and cancer biology". Semin. Cancer Biol. 20 (5): 329–39. doi:10.1016/j.semcancer.2010.10.002. PMC   3040982 . PMID   20934517.
  88. Wang L, Xie L, Wang J, Shen J, Liu B (2013). "Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer". BMC Gastroenterol. 13: 173. doi:10.1186/1471-230X-13-173. PMC   3877991 . PMID   24359226.
  89. Bird JL, Jennert-Burston KC, Bachler MA, Mason PA, Lowe JE, Heo SJ, Campisi J, Faragher RG, Cox LS (2012). "Recapitulation of Werner syndrome sensitivity to camptothecin by limited knockdown of the WRN helicase/exonuclease". Biogerontology. 13 (1): 49–62. doi:10.1007/s10522-011-9341-8. PMID   21786128. S2CID   18189226.
  90. Masuda K, Banno K, Yanokura M, Tsuji K, Kobayashi Y, Kisu I, Ueki A, Yamagami W, Nomura H, Tominaga E, Susumu N, Aoki D (2012). "Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells". Oncol. Rep. 28 (4): 1146–52. doi:10.3892/or.2012.1912. PMC   3583574 . PMID   22797812.
  91. Futami K, Takagi M, Shimamoto A, Sugimoto M, Furuichi Y (2007). "Increased chemotherapeutic activity of camptothecin in cancer cells by siRNA-induced silencing of WRN helicase". Biol. Pharm. Bull. 30 (10): 1958–61. doi: 10.1248/bpb.30.1958 . PMID   17917271.
  92. Futami K, Ishikawa Y, Goto M, Furuichi Y, Sugimoto M (2008). "Role of Werner syndrome gene product helicase in carcinogenesis and in resistance to genotoxins by cancer cells". Cancer Sci. 99 (5): 843–8. doi:10.1111/j.1349-7006.2008.00778.x. PMID   18312465. S2CID   21078795.

Bibliography